eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi

EUROINVENT 2013
Description EN
Class no.
Aim: Increasing significantly the effectiveness of primary
vaccination against viral hepatitis B, extension of the duration
of protection against this infection.
Solution: Since the age of one year, annually must be
determined the level of anti-HBs, and if anti-HBs level is from
10 to 150 mIU / ml must be administrated a booster dose of
vaccine against HBV, and if the anti-HBs level is less than 10
mIU / ml must be administered a repeated course of three or
four doses of vaccine against HBV.
Advantages: A booster dose of vaccine against hepatitis B
must be applied when the anti-HBs titre is found between the
limit of 10-150 mIU / ml, because this level is considered
protective, but not sufficient to ensure protection lasting.
4. Medicine - Health Care - Cosmetics
8.59.
Title
A diagnostic procedure infections caused by
Enterobacteriaceae producing beta-lactamase
Authors
O. BURDUNIUC., R. COJOCARU., C. SPÎNU., S.
GHEORGHIȚĂ, I. ROȘCIN
Institution
National Center for Public Health
Republic of Moldova
Patent no. MD7438 2013
Enterobacteriaceae family organisms producing betalactamases.
Solution: Diagnosis of infections causes by Enterobacteriaceae
producing beta-lactamases are carried by screening with
multiplex PCR and using reference strains (E. coli profile
ESBLs CTX-M1, CTX-M-3, CTX-M-14, CTX-M-15
phylogenetic group A, E. coli profile ESBLs CTX-M 3, CTX-
Description EN M-14, CTX-M-15 from phylogenetic group B2 E. coli profile
ESBLs CTX-M-14, CTX-M-15 group phylogenetic D), and
when is identified new strains, profile is established by
sequencing method with further adding in the list of reference
strains.
Advantages: updating case management regarding diagnosis
and treatment of patients with infections caused by
Enterobacteriaceae producing beta-lactamases
Class no. 4. Medicine - Health Care - Cosmetics
INTERNATIONAL EXHIBITS
105